JW Asset
VC Fund
JW Asset is a VC fund focused on Biotechnology and Chemical. South Korean Investment Firm
- Total investments:
- 5
- Last investment:
- Lead investor:
- 20%
Last updated:
For AI agents: llms.txt
Industries JW Asset invests in
Stages JW Asset invests in
Countries JW Asset invests in
Investment Focus
Industry
- Biotechnology 2 (40%)
- Chemical 1 (20%)
- Genetics 1 (20%)
- Health Care 1 (20%)
- Therapeutics 1 (20%)
Stage
- Series A 3 (60%)
- Seed 1 (20%)
- Series C 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
DaNAgreen
|
DaNAgreen provides crosslink proteins to make scaffolds that help scientists culture cells in 3D. Their scaffolds can be easily manipulated in typical cell culture dishes, plates, and inserts in standardized procedures. | $6.8M / Series A / Dec 29, 2021 | |
3billion
|
3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable forpatients in need.The company was established in 2016 and is headquartered in Seoul, South Korea. | $13M / Series C / Mar 26, 2021 | |
|
DaNAgreen
|
DaNAgreen provides crosslink proteins to make scaffolds that help scientists culture cells in 3D. Their scaffolds can be easily manipulated in typical cell culture dishes, plates, and inserts in standardized procedures. | $1.3M / Seed / Aug 20, 2020 | |
Xcell Therapeutics
|
Xcell Therapeutics operates as a pharmaceutical company that engages in the development and production of drugs for cell therapy. The Company researches, develops and manufactures Xcell Therapeutics, clonally selected MSCs, automated mass cell culture, MSC-derived exosomes, and other related products. In addition, it develops media for cellculture in various areas of the bioindustry, such as cell therapy, gene therapy, exosomes, organoids and bioreactors. | $4.8M / Series A / Jan 01, 2019 | |
|
3billion
|
3billion was founded with the goal of ending the diagnostic odyssey of rare disease patients through comprehensive genetic testing. It has reduced the amount of time and cost that was previously required for genome interpretation by using bioinformatics and machine learning technology, making genome-scale rare disease genetic testing affordable forpatients in need.The company was established in 2016 and is headquartered in Seoul, South Korea. | $2.2M / Series A / Jul 11, 2018 |
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does JW Asset invest in?
JW Asset invests primarily in Biotechnology, Chemical and Genetics startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did JW Asset last invest?
The most recent investment recorded for JW Asset closed in Dec 2021. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
